Skip to main content
SP5007,631.47-0.71%DOW52,766.88-0.79%NASDAQ26,099.77-1.03%BTC$76,632.00-1.75%ETH$2,376.39-2.83%GOLD$4,384.40-0.27%OIL$89.72-0.55%
Smart Investors Daily
GM

NYSE · GMED

Globus Medical, Inc.

Healthcare · Medical - Devices

$80.48

Down-$0.89 (-1.09%)

Updated Sep 2, 2026, 1:03 PM

SID Score

5.7/10

Composite research score

Smart Money

58/100

Neutral

Market cap
11.89B
P/E ratio
28.2
Dividend yield
0.00%
52-week range
$54.15 – $101.40
Volume
1.05M
Avg. volume
1.73M

Price performance

GMED price history

1M range · 21 trading sessions · Daily adjusted prices

GMED closed at $80.48 after 21 trading sessions, down 1.26% for the selected period.

Last close
$80.48
Period change
-1.26%
Period low
$80.48
Period high
$88.34
Daily close
View OHLC price history
GMED OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 1, 2026$81.46$82.89$79.69$80.481.05M
Aug 31, 2026$82.07$82.145$81.00$81.371.03M
Aug 28, 2026$82.61$83.53$81.80$82.971.06M
Aug 27, 2026$82.02$84.01$81.67$82.54846.24K
Aug 26, 2026$82.50$83.855$81.81$83.10970.83K
Aug 25, 2026$83.99$84.4992$82.96$82.961.02M
Aug 24, 2026$86.92$87.2699$83.615$84.081.13M
Aug 21, 2026$85.57$87.1643$85.26$86.91930.8K
Aug 20, 2026$87.83$88.3967$85.62$85.67848.04K
Aug 19, 2026$87.33$88.89$86.98$88.341.06M
Aug 18, 2026$85.01$87.46$85.01$86.441.17M
Aug 17, 2026$85.05$85.57$84.46$85.121.08M
Aug 14, 2026$84.74$86.42$84.74$85.90864.75K
Aug 13, 2026$85.84$86.37$84.62$85.941.39M
Aug 12, 2026$84.28$85.73$83.16$85.671.09M
Aug 11, 2026$85.85$86.86$84.70$85.151.84M
Aug 10, 2026$81.62$86.295$81.40$86.153.02M
Aug 7, 2026$88.12$88.12$80.71$82.353.3M
Aug 6, 2026$81.00$81.41$78.79$81.082.2M
Aug 5, 2026$80.71$81.16$79.87$80.541.39M
Aug 4, 2026$80.64$81.60$80.00$81.511.21M

Latest GMED news

The latest Smart Investors Daily articles mentioning GMED.

Stock researchCompany · Overview

GMED research

Overview

Company profile and research snapshot.

Company profile

Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States. It also has its presence internationally.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$76.00
Implied upside
—
Analysts
—
GMED recent ratings
DateFirmRatingTarget
Aug 7, 2026Wells FargoOverweight—
Jul 28, 2026UBSNeutral—
Jul 16, 2026Truist SecuritiesBuy—
Jul 13, 2026RBC CapitalOutperform—
Jul 9, 2026BMO CapitalOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Feb 27, 2026

Globus Medical Record Q4 And Synergies Refocus Valuation And Growth Debate

Globus Medical (NYSE:GMED) reported record Q4 and full year results, supported by its U.S. Spine and Trauma businesses and Enabling Technologies segment. The company completed integrations of NuVasive and Nevro, with NuVasive synergies reaching $200 million nearly a year ahead of the original timetable. Globus Medical repaid acquired convertible debt and signaled plans to increase R&D and product development investment. For context, Globus Medical shares most recently traded at $96.71. The...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By